Tryton Awarded Patent for Innovative Side Branch Stent System

DURHAM, N.C.–(BUSINESS WIRE)–Tryton Medical, Inc., the leading developer of stents designed to
definitively treat bifurcation lesions, announced today that a U.S.
patent has been awarded for the company’s Tryton Side Branch Stent™
System.

The Tryton Side Branch Stent offers a dedicated strategy for treating
atherosclerotic lesions at a bifurcation. These lesions have presented a
challenge for cardiologists since the earliest days of angioplasty.
Current approaches to treating these bifurcation lesions have
limitations, most often neglecting the side branch. In cases where the
side branch is treated it is often left unstented, leaving it vulnerable
to higher rates of restenosis, the re-narrowing of a treated blood
vessel.

“We’re very pleased that a United States patent has been awarded to
Tryton Medical for the unique Tryton Side Branch Stent System, which is
treating some of the most challenging interventional cases in
cardiovascular disease,” said J. Greg Davis, president and CEO of Tryton
Medical.

“This patent represents an important milestone for the company and our
investors and is one of a family of patents currently under review at
the Patent Office” added Chief Technical Officer H. Richard Davis.

About the Tryton Side Branch Stent System

The Tryton Side Branch Stent System is designed to offer a dedicated
strategy for treating atherosclerotic lesions in the side branch at the
site of a bifurcation. These areas of the vascular system are a common
location for plaque and are particularly challenging to treat with
currently available stent systems. Approximately twenty percent of
patients treated for coronary artery disease have diseased bifurcated
lesions.

Tryton’s highly deliverable cobalt chromium stent is deployed in the
side branch artery using a standard single-wire balloon-expandable stent
delivery system. A conventional drug-eluting stent is then placed in the
main vessel.

The Tryton Side Branch Stent System demonstrated excellent six-month
clinical results in a first-in-man study of the system in 30 patients,
with no restenosis occurring in the side branch artery. The stent system
has received CE Mark approval in Europe and is not approved in the
United States.

About Tryton Medical, Inc.

Tryton Medical, Inc., located in Durham, N.C., is a leading developer of
novel stent systems for the treatment of bifurcation lesions. The
company’s Side Branch Stent System, approved for sale in Europe, is
designed to offer a dedicated strategy for treating these challenging
cases. The privately held company is backed by Spray Ventures, PTV
Sciences and RiverVest Ventures. For more information please visit trytonmedical.com.